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Background: A marked reduction in serum levels of bioactive insulin-like growth factor-I (IGF-I) has been observed
in fasting hemodialysis (HD) patients during a 4-h HD session. The aim of the present study was to investigate the
beneficial effect of hyperinsulinemia during HD on bioactive IGF-I and inflammatory biomarkers.
Methods: In a randomized cross-over study, 11 non-diabetic HD patients received a standardised HD session with
either: 1) no treatment, 2) glucose infusion (10% glucose, 2.5 mL/kg/h), or 3) glucose-insulin infusion (10% glucose
added 30 IU NovoRapidW per litre, 2.5 mL/kg/h). Each experiment consisted of three periods: pre-HD (−120 to
0 min), HD (0 to 240 min), and post-HD (240 to 360 min). A meal was served at baseline (−120 min); infusions were
administered from baseline to 240 min. The primary outcome was change in bioactive IGF-I during the experiment.
Secondary outcomes were changes in high-sensitivity C-reactive protein, interleukin-1β, interleukin-6, and tumor
necrosis factor α. Comparisons were performed using mixed-model analysis of variance for repeated measures.
Results: From baseline to the end of study, no significant differences were observed in the changes in either serum
bioactive IGF-I or total IGF-I between study days. Overall, serum bioactive IGF-I levels rose above baseline at 120 to
300 min with a maximum increase of 20% at 120 min (95% confidence interval (CI), 9 to 31%; p < 0.001), whereas
total IGF-I levels rose above baseline at 180 to 300 min with a maximum increase of 5% at 240 min (95% CI, 2 to
9%; p = 0.004). A significant difference was observed in the changes in serum IGF-binding protein-1 (IGFBP-1)
between study days (p = 0.008), but differences were only significant in the post-HD period. From baseline to the
end of HD, no significant difference was observed in the changes in serum IGFBP-1 levels between study days, and
in this time period overall serum IGFBP-1 levels were below baseline at all time points with a maximum decrease of
51% at 180 min (95% CI, 45 to 57%; p < 0.001). None of the investigated inflammatory biomarkers showed any
differences in the changes over time between study days.
Conclusions: Postprandial insulin secretion stimulated the IGF-system during HD with no further effect of adding
glucose or glucose-insulin infusion. Hyperinsulinemia during HD had no effect on biomarkers of inflammation.
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Table 1 Patient characteristics at baseline
Variable n = 11
Age (years) 58 (33–79)
Sex (males/females) 8/3
Body mass index (kg/m2) 24.9 ± 3.6
Subjective global assessment score (A/B) 5/6
Hemodialysis vintage (months) 35 (11–232)
Dialysis days per week (2/3/4 days) 1/8/2
Urine production ≥ 200 mL/day (yes/no) 4/7
Kt/V 1.58 ± 0.38
Normalized nitrogen protein appearance
rate (nPNA) (g/kg/day)
0.91 ± 0.16
Plasma albumin (g/L) 38.8 ± 2.1
pH 7.43 ± 0.03
S-HCO3- (mmol/L) 25.5 ± 2.0
Blood glucose (mmol/L) 5.2 ± 0.4
Serum insulin (pmol/L) 33.9 ± 19.1
Serum bioactive IGF-I (μg/L) 0.83 ± 0.27
Serum total IGF-I (μg/L) 124 ± 43
Serum IGFBP-1 (μg/L) 267 ± 147
Serum IGFBP-2 (μg/L) 1949 ± 1112
Data are mean ± SD, median (range), or number.
At baseline no differences were observed in biomarker concentrations
between study days and overall mean concentrations are shown.
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Protein-energy wasting (PEW) is frequent in maintenance
hemodialysis (HD) patients and an independent predictor
of morbidity and mortality [1]. Causes of PEW in main-
tenance HD patients include reduced intake of energy and
protein, resistance to the actions of anabolic hormones
such as insulin, growth hormone (GH), and insulin-like
growth factor-I (IGF-I) [2-5], and non-specific inflamma-
tory processes [6-9]. Moreover, HD per se stimulates
muscle and whole body protein loss which further in-
creases the risk of PEW [10-12]. Amino acid kinetic stud-
ies have demonstrated that HD in the postabsorptive state
induces muscle protein loss by increased muscle protein
breakdown [13]. Muscle protein breakdown is stimulated
by the release of proinflammatory cytokines induced by
contact of blood cells with the dialyser membrane and
bacterial-derived DNA fragments in the dialysis fluid
[6,14,15]. Of note, there is a positive correlation between
interleukin-6 (IL-6) levels and muscle protein breakdown,
and as IL-6 levels peak after completion of the HD pro-
cedure a considerable protein catabolic “carry-over effect”
may extend to the post-HD period [16].
IGF-I is an important regulator of muscle metabolism
and stimulates muscle protein anabolism in both animals
[17,18] and humans [19,20]. More than 99% of the circu-
lating IGF-I pool is complexed to specific high-affinity
IGF-binding proteins (IGFBPs) that regulate the bioavail-
ability of IGF-I to its tissue receptors [21]. Hence, changes
in the binding capacity of the IGFBPs may result in
marked changes in serum free and thereby bioactive IGF-I
without causing any change in serum total IGF-I [22].
Supportive of this notion, we recently reported that HD
performed in overnight fasting patients resulted in a marked
up-regulation of serum IGFBP-1, the only short-term regu-
lated IGFBP, and a corresponding down-regulation of free
and bioactive IGF-I without any concomitant change in total
IGF-I [23]. These results may reflect the protein catabolic
nature of HD in the fasting state and, moreover, they may
explain why previous amino acid kinetic studies in HD pa-
tients failed to show any association between changes in
muscle protein metabolism and serum total IGF-I [10,24].
The IGF-system interacts with inflammatory proteins.
Experimental animal studies have demonstrated that in-
fusion of tumor necrosis factor α (TNF-α) in rats in-
creases the hepatic mRNA expression and protein
secretion of IGFBP-1, whereas those of IGF-I are de-
creased [25]. In addition, in uremic rodents chronic or
sepsis-induced inflammation reduces serum IGF-I levels,
IGF-I gene expression, and muscle net protein synthesis;
changes that can be reversed or ameliorated by pharma-
cological blockage of the proinflammatory cytokines
IL-1, IL-6, and TNF-α [26-28].
Insulin inhibits the hepatic IGFBP-1 production and
may therefore indirectly stimulate the actions of IGF-Iin vivo [29,30]. Furthermore, insulin appears to exert
anti-inflammatory effects [31,32]. Therefore, we hypoth-
esized that maintenance of hyperinsulinemia during HD
by either glucose or glucose-insulin infusion would sup-
press the HD-induced decrease in serum bioactive IGF-I
as well as the increase in plasma IL-6.Methods
Study participants
Twelve non-diabetic patients were enrolled in this study
which was conducted between November 2010 and July
2011 at Aarhus University Hospital. One patient with-
drew before completing the study and was omitted from
data analysis. Patients included were older than 18 years,
on stable maintenance HD for at least 3 months, and
had well-functioning arteriovenous fistulas with recircu-
lation less than 5%. Exclusion criteria were diabetes
mellitus, body mass index (BMI) below 18.5 or above
30.0 kg/m2, malnutrition (subjective global assessment
score C), active malignant disease, immunosuppressive
treatment (including glucocorticoid treatment), evidence
of an ongoing inflammatory disease, or pregnancy. Base-
line characteristics are presented in Table 1. The diagno-
ses were chronic glomerulonephritis (n = 2), autosomal
dominant polycystic kidney disease, (n = 2), medullary
cystic kidney (n = 1), granulomatosis with polyangiitis
(n = 1), and chronic renal failure of unknown origin (n = 5).
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Five patients had 0 comorbidities (low risk), 5 patients had
1–2 comorbidities (medium risk), and 1 patient had ≥3
comorbidities (high risk). Four patients smoked 10 to 20
cigarettes a day. Medication was unchanged during the
study period. The study was performed in accordance
with the Declaration of Helsinki and monitored by the
Committee of Good Clinical Practice at Aarhus University
Hospital. Protocol and consent forms were approved by
the local research Ethics Committee (Central Denmark Re-
gion), and all participating patients gave written informed
consent. This trial is registered with the ClinicalTrials.gov
registry: NCT01209403.
Study design
In this randomized, controlled cross-over study, patients
received a standardised HD session with either 1) no
treatment (NT), 2) continuous intravenous infusion of
glucose 10% at a rate of 2.5 mL/kg/h (G), or 3) continu-
ous intravenous infusion of glucose 10% added 30 IU of
insulin aspart (NovoRapidW, Novo Nordisk A/S,
Bagsværd, Denmark) per litre at a rate of 2.5 mL/kg/h
(GI). The three experiments were separated by two
weeks wash-out period. In two cases the experiments
were postponed for 5 days because the patients were un-
able to participate the scheduled day, and in one case
the investigation was postponed for three weeks due to
an acute upper gastrointestinal bleeding.
Experimental study day
The experimental design is depicted in Figure 1. After an
overnight fast, patients met between 7:30 and 9:00 AM at
the Dialysis Department at Aarhus University Hospital.
Participants were instructed to meet at the same time on
each of the three study days. The experiments lasted eight
hours, and each experiment was divided into a pre-HD
period (2 hrs), a HD period (4 hrs), and a post-HD period
(2 hrs). In the pre-HD period, dialysis needles wereTime -120 -60 0 60 1
Pre-HD period (2h) HD per
Breakfast 
tratsnoisufnI




















Figure 1 Experimental design. Abbreviations: F, fasting samples; B, blood
AV, both arterial and venous sites for insulin/insulin aspart samples.inserted in the arteriovenous shunt and fasting blood sam-
ples collected before a standardised breakfast meal was
served. The breakfast meal consisted of bread, butter,
ham, cheese, jam, and honey and was served with either
coffee or tea. The meal had to be ingested within the first
hour of the pre-HD period and the type and amount of
food ingested was registered in order to calculate intake of
energy (NT: 9.2 ± 2.9; G: 8.1 ± 2.8; GI: 9.8 ± 2.9 kcal/kg)
and protein (NT: 0.28 ± 0.07; G: 0.26 ± 0.06; GI: 0.31 ±
0.07 g/kg). Unintentionally, the mean energy intake
was significantly higher on GI than on G study days
(p = 0.007). Otherwise no significant differences in en-
ergy or protein intake were observed between study
days. After the meal only sips of water and ice cubes
were permitted until the end of the experiment. On
the treatment days, infusions of either G or GI were
commenced immediately after collection of fasting
blood samples, using a second catheter inserted in the
contra-lateral arm. G and GI were infused during the
pre-HD and HD period and blood glucose levels (BG)
were maintained at 8.0-10.0 mmol/L by additional glu-
cose infusion. In the post-HD period, insulin infusion
was stopped and glucose infusion was tapered off
according to BG levels targeted at 3.0-5.0 mmol/L to
avoid severe hypoglycaemia.Hemodialysis
HD was delivered as a standardised 4-h lasting HD session
using a blood flow of 300 mL/min, a dialysate flow of
500 mL/min, and a high-flux polysulphone membrane
(FX80, Fresenius Medical Care, Bad Homburg, Germany).
Ultrafiltration was scheduled to be linear throughout the
HD session and to compensate for the extra volume load
given due to G and GI infusion to obtain previously
established “estimated dry weight”. The same dose of
low-molecular-weight heparin was used in all three ex-
periments. A standardised dialysate containing glucose
5.5 mmol/L, sodium 138 mmol/L, potassium 2.0 mmol/L,20 180 240 300 360  
iod (4h) Post-HD period (2h)
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glucose; A, ABL gas analyzer; H, hormones; I, inflammatory biomarkers;
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was used.
Assays
Samples for Radiometer ABL 800 Flex blood gas analyzer
(Radiometer Medical, Brønshøj, Denmark) were analyzed
every hour throughout the experiment to monitor electro-
lytes (especially potassium), BG levels, and hematocrit. In
addition, BG levels were measured with glucometer
(HemoCue Glucose 201 DM, HemoCue AB. Ängelholm,
Sweden) to obtain BG measurements every 30 min. In
the post-HD period, BG levels were measured every
10–30 min to avoid hypoglycaemia.
Plasma concentrations of albumin, fibrinogen, and
25-hydroxy vitamin D were determined with routine
automated methods at the Department of Clinical Bio-
chemistry, Aarhus University Hospital. For measure-
ments of hormones and inflammatory biomarkers
serum and plasma were separated by centrifugation at
3500 g for 10 min at 4°C and aliquots were stored
within an hour at −80°C until further processing.
Serum levels of immunoreactive (total) IGF-I (final dilution
1:1000) were determined in acid ethanol serum extracts using
a validated, in-house time-resolved immunofluorometric
assay (TR-IFMA) as previously described [34] with slight
modifications: first, the IGF-I assay had been calibrated
against the international IGF-I reference preparation
WHO 02/254. Second, the detection antibody now con-
sists of a biotinylated goat polyclonal antibody (Sigma-Al-
drich, catalogue No. I-8773; Brøndby, Denmark). The
biotinylated antibody was incubated with streptavidin
europium obtained from Perkin Elmer Life Sciences
(Turku, Finland).
Bioactive IGF-I was analysed by a cell-based kinase-
receptor activation (KIRA) assay based on human em-
bryonic cells transfected with cDNA of the human IGF-I
receptor (IGF-IR) gene, as previously detailed [35], with
slight modifications. The assay measures the ability of
serum IGF to phosphorylate (i.e. activate) the IGF-IR
in vitro, and takes into account the presence of the
IGFBPs and their ability to modify IGF-IR activation by
IGF-I or IGF-II [36]. In brief, transfected cells were stim-
ulated with serum diluted 1:10 in Krebs-Ringer buffer
for 15 min at 37°C, after which cells were aspirated and
the cells lysed. The crude cell lysates were then trans-
ferred to a TR-IFMA assay specific for phosphorylated
(i.e. ligand-activated) IGF-IRs, based on a monoclonal
capture antibody against the extracellular IGF-IR domain
and an europium-labelled monoclonal anti-phosphotyrosine
antibody as tracer. Since the original description [35], the
KIRA assay has been slightly modified. The assay has now
been calibrated against the international IGF-I reference
preparation WHO 02/254. Furthermore, the antibodies of
the phosphorylated IGF-IR TR-IFMA have been changed.Coating is now performed using the monoclonal anti-
body (part 841431, 4 mg/l) contained in the human
phospho-IGF-IR kit from R&D Systems (catalogue no
DYC 1770E). For detection we use the biotinylated
monoclonal phosphotyrosine antibody BAM 1676
(2 mg/l; R&D Systems). The latter is co-incubated with
streptavidin europium.
In the KIRA assay, the ability of serum to phosphoryl-
ate the IGF-IR in vitro is compared of a serial dilution of
rh-IGF-I (WHO 02/254), and accordingly, it is possible
to express the serum signal in IGF-I concentrations. The
KIRA also detects IGF-II and pro-IGF-II activation of
the IGF-IR with a cross-reactivity of 12% and 2%, re-
spectively, of that of IGF-I, whereas proinsulin, insulin
and insulin analogues have a cross reactivity <1%. The
KIRA has a detection limit <0.08 μg/l, and intra- and
inter-assay CVs averaging <7% and <15%, respectively.
IGFBP-1 was assayed by an in-house TR-IFMA, which
represents a modification of our previously described
RIA [37]. In brief, microtiter plates (Nunc, Roskilde,
Denmark) were coated with 100 μL per well of MAB
6303 (Medix Biochemica, Kauniainen, Finland, 1 mg/L
dissolved in phosphate buffer, 40 mM, pH 8.0) and incu-
bated overnight at 5°C. MAB 6303 recognizes all phos-
phorylated isoforms of human IGFBP-1 [38]. Next day,
all wells were washed once (PBS, pH 7.4 added 0.5%
(vol/vol) Tween 20 and 0.05% (wt/vol) NaN3) before
they were blocked (40 mM phosphate buffer, pH 8.0,
added 5% (vol/vol) Tween 20 and 25 μM EDTA). After
2 hrs of blocking at room temperature, the wells were
washed once and added 100 μL antigen. Purified human
amniotic IGFBP-1 (catalogue no 8IGB1, HyTest, Turku,
Finland) served as standard (range: 1.56-50 μg/L). Serum
was diluted 1:10. All antigens were dissolved in assay
buffer (40 mm phosphate, pH 8.0, added 25 μM EDTA,
0.1% (wt/vol) bovine serum albumin, 0.05% (wt/vol)
NaN3, 0.9% (wt/vol) NaCl and 1% (vol/vol) Tween 20))
and assayed in duplicates, whereas non-specific binding
(NSB) was assayed in quadruplicate. After an overnight in-
cubation at 5°C, the wells were washed and added 100 μL
(400 μg/L) of polyclonal rabbit antibody directed against
human IGFBP-1 (catalogue no sc-13097, Santa Cruz Bio-
technology, Heidelberg, Germany) dissolved in assay buf-
fer. After two hours of incubation at room temperature all
wells were washed and added 100 μL biotinylated goat
anti-rabbit IgG (catalogue no. BAF008, R&D Systems) to-
gether with Europium-labeled streptavidin added in a final
dilution of 1:1000. After two hours incubation at room
temperature all wells were washed 6 times, added en-
hancement solution (200 μL/well, Perkin Elmer Life
Sciences, Turku, Finland) and read using time-resolved
fluorometry. The coating antibody MAB 6303 has pre-
viously been shown to neglect rhIGF-I and -II as well
as rhIGFBP-2, -3, -4, and −5 in concentrations up to
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below the lowest standard (the signal to NSB ratio cor-
responding to the lowest and highest standards aver-
aged approximately 7 and 70, respectively). The intra-
assay CV of samples assayed in duplicates averaged
less than 5%, the inter-assay CV of an internal control
(IGFBP-1 standard) and a control serum sample aver-
aged 8.1 and 7.0%, respectively (22 plates).
IGFBP-2 was assayed by an in-house TR-IFMA as pre-
viously detailed with an intra- and inter-assay CV of <
5% and < 12% respectively [37].
Serum insulin was measured by a commercially avail-
able TR-IFMA (AutoDELFIA insulin; Perkin Elmer Life
Sciences). Insulin aspart (NovoRapidW) measurements
were generously performed at the laboratories of Novo
Nordisk A/S (Måløv, Denmark) using a homogenous im-
munoassay with analogue-specific antibody for insulin
aspart determination.
Plasma cytokines (IL-1β, IL-6, and TNF-α) were mea-
sured in a magnetic Bio-Plex Pro Assay (Bio-Rad, Hercules,
CA, USA), as described by the manufacturer. Detection
limits were between 0.5 and 1 ng/L. A Luminex100 using
the BioPlex Manager 6.0 software (BioRad) was used
for analysis.
High-sensitivity CRP (hsCRP) was determined by an
in-house TR-IFMA assay based on two commercial
monoclonal antibodies (catalogue no. MAB17071 and
BAM 17072 obtained from R&D Systems). The assay
was performed essentially as described for the IGFBP-1
assay. As standard we used a preparation from NIBSC
(1st international standard, NBISC code 85/506, Potters
Bar Hertforshire, UK). The intra- and inter-assay CVs
averaged less than 5 and 11%, respectively.
Standardisation for comparison
Due to the extra volume infused on G and GI study days,
the mean ultrafiltration varied between treatment days (NT:
2,398 ± 1,055; G: 3,039 ± 783; GI: 3,378 ± 645 mL), and was
significantly higher on G (p = 0.003) and GI (p < 0.001) study
days compared with NT study days, whereas there was no
difference between G and GI study days. Despite the differ-
ence in mean ultrafiltration, the change in mean hematocrit
during the experiments did not differ between study days
(p = 0.72). Prior to the statistical analysis bioactive IGF-I,
total IGF-I, IGFBP-1, IGFBP-2, insulin, insulin aspart, al-
bumin, fibrinogen, hsCRP, IL-1β, IL-6, and TNF-α con-
centrations obtained from each patient were corrected for
changes in hematocrit using the formula [39]:
corX ¼ X  1 Htxð Þ
1 Htbaselineð Þ
where corX represents the corrected value for the tested
compound X, the observed value for the tested compound,Htx the hematocrit value at the sampling time, and
Htbaseline the hematocrit value measured at baseline.
Other measurements
Subjective global assessment (SGA) score was used to
classify patients into three categories according to their
nutritional status: A, good nutritional status; B, moder-
ate malnutrition; C, severe malnutrition [40]. Kt/V and
the normalized nitrogen protein appearance rate were
evaluated by the urea kinetic model. The percentage re-
moval fraction (RF) of serum insulin and insulin aspart
by the dialysis membrane was calculated at the begin-
ning (t = 0 min), midway (t = 120 min), and at the end
(t = 240 min) of the HD session from the geometric
mean ratio between insulin and insulin aspart concen-
trations at the arterial and venous sites of the dialyser.
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD), unless otherwise stated. Changes in biochemical
markers over time between and within the different
study days (NT, G, and GI) were tested after logarithmic
transformation of the original data with mixed-model
analysis of variance (ANOVA) for repeated measures
with Greenhouse-Geisser epsilon correction. In the
ANOVA models, time was the repeated factor, individ-
uals and their interaction with day of visit were random
factors; order of study days, day of visit, study day, time,
and the interaction between study day and time were
fixed factors. When there was a significant interaction
between study day and time, study days were compared
pairwise, and finally differences between non-parallel
curves were assessed at each time point. When no sig-
nificant interaction was identified between study day and
time, results from the three study days were pooled and
main effects of time on overall concentrations of the
biochemical marker evaluated. The percentage change
from baseline was calculated from the geometric mean
ratio between concentrations at baseline and at the spe-
cific time point obtained by taking antilog to the differ-
ences derived from the ANOVA models (in a log-scale).
Normality was checked by QQ-plots of the residuals.
Changes in insulin and insulin aspart concentrations be-
tween the arterial and venous sites of the dialyser were
assessed by Student’s paired t-test. The percentage re-
moval fraction (RF) of circulating serum insulin by the
dialysis membrane was estimated from the geometric
mean ratio between insulin concentrations at the arterial
and venous sites obtained by taking antilog to the esti-
mated difference between means of log-transformed in-
sulin concentrations at the arterial and venous sites.
Assumptions were assessed with QQ-plots of differences
and Bland-Altman plots. Associations between variables
were assessed with the random coefficient model and
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Residuals were assessed graphically and logarithm trans-
formation of the exposure variable was performed if
needed. P-values ≤ 0.05 were considered statistically sig-
nificant. Data were analysed using Stata version 11.1
(Lakeway Drive, Texas, USA).
Sample size calculation
In a previous study on 10 non-diabetic HD patients we
found the mean concentrations ± SD of bioactive IGF-I
to be 1.07 ± 0.41 μg/L. A difference of 20% (0.2 × 1.07 =
0.21 μg/L) was considered to be the relevant difference
between study days. With a level of significance of 5%
and a power of 80%, 10 subjects needed to be included
in the study as the SD of the difference was estimated to
be half the SD of the population SD. In order to
randomize subjects equally between order of study days
(6 possible combinations) and allow for drop-outs,
12 subjects were included in the study. Randomization
was done in two blocks and each block contained the 6
different combinations of study days.
Results
Blood glucose, glucose infusion rates, and serum insulin
Figure 2 depicts BG levels, glucose infusion rates, and
serum total insulin (insulin + insulin aspart) concentra-
tions on study days. Mean BG levels were comparable
at baseline (NT: 5.3 ± 0.4; G: 5.1 ± 0.5; GI: 5.1 ± 0.4 -
mmol/L, p = 0.13), but a significant difference in the
changes over time were observed between study days
(p < 0.001). During the experiments, BG levels were
higher on G (p < 0.001) and GI (p = 0.02) study days com-
pared with NT study days. BG levels were lower on GI
than on G study days (p = 0.01) although the total amount
of infused glucose was significantly higher on GI than onFigure 2 Blood glucose and serum insulin levels. Blood glucose levels (
the experiments on no treatment (NT) (black circles), glucose infusion (G) (
days. In plot C dark bars equal insulin and light bars equal insulin aspart lev
point. Data are expressed as means.G study days (2.61 ± 0.23 vs 1.94 ± 0.22 g/kg, p < 0.001).
On GI study days, a pronounced decline in BG levels was
observed immediately after glucose infusions were tapered
off after the HD session. Hence, 30 min post-HD BG
levels reached their nadir values on GI study days and
were significantly lower than on G study days (3.8 ± 1.3 vs
5.7 ± 1.1 mmol/L, p < 0.001). Total insulin concentrations
differed significantly between study days at 0, 120, and
240 min (p < 0.001 for each pairwise comparison), whereas
no differences were observed at baseline or at 360 min.
Serum bioactive IGF-I and total IGF-I
No significant differences were observed in the changes
over time in either serum bioactive IGF-I or total IGF-I
between study days (Figure 3). Overall, postprandial
serum levels of bioactive IGF-I rose above baseline at
120 to 300 min (p < 0.014 for each) with a maximum in-
crease of 20% at 120 min (95% confidence interval (CI),
9 to 31%; p < 0.001). Overall, serum total IGF-I levels
showed only modest deviations from baseline during the
experiments. After a transient fall of 6% at 0 min (95%
CI, 3 to 9%; p < 0.001), total IGF-I levels rose above
baseline at 180 to 300 min with a maximum increase of
5% at 240 min (95% CI, 2 to 9%; p = 0.004). Bioactive
IGF-I was positively related with the logarithm of total
IGF-I (p < 0.001, slope coefficient = 0.59) and with the
logarithm of total insulin (p = 0.03, slope coefficient =
0.02), and negatively associated with the logarithm of
IGFBP-1 (p < 0.001, slope coefficient = − 0.12).
Serum IGFBP-1 and IGFBP-2
A significant difference was observed in the changes in
serum IGFBP-1 between study days (p = 0.008) (Figure 3).
Differences were only found between NT and G study days
and restricted to the post-HD period, where IGFBP-1 levelsA), glucose infusion rates (B), and serum total insulin levels (C) during
open circles), and glucose-insulin infusion (GI) (black triangles) study
els. αp < 0.001 vs NT and βp < 0.001 vs G study days at same time
ATime (min)
























































































Figure 3 Serum bioactive IGF-I, total IGF-I, IGFBP-1, and IGFBP-2. Bioactive IGF-I (A), total IGF-I (B), IGFBP-1 (C), and IGFBP-2 (D) changes
during the experiments on no treatment (black circles), glucose infusion (open circles), and glucose-insulin infusion (black triangles) study
days. αp < 0.003 for NT vs G and βp < 0.02 for NT vs GI study days. Data are expressed as mean ± SEM.
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and 360 min). From baseline to the end of HD, no significant
differences were observed in the changes in serum IGFBP-1
levels between study days (p = 0.25), and in this time period
overall serum IGFBP-1 levels were below baseline at all time
points (p < 0.001 for each) with a maximum decrease of 51%
at 180 min (95% CI, 45 to 57%). A significant difference was
observed in the changes in serum IGFBP-2 between study
days (p = 0.036), and further evaluation showed a difference
between NT and GI study days (p = 0.013) (Figure 3).
IGFBP-1 was negatively related with the logarithm of total
insulin (p < 0.001, slope coefficient =− 22), whereas the same
was not observed for IGFBP-2.
Present findings compared with previous findings on
fasting HD patients
In the present study all subjects received a meal prior to
HD, and they also received a glucose-containing dialysate.By contrast, in our former study we investigated ten over-
night fasted non-diabetic HD patients, who remained fasting
throughout the entire HD session. Furthermore, in that
study we used a glucose-free dialysate, but otherwise we
used a similar HD setting (4-h HD sessions using a high-
flux membrane) and a similar patient group (male/female:
8/2, mean age 52.5 ± 5.7 years, BMI 26.2 ± 1.3 kg/m2, and
no signs of inflammation or malnutrition) [23] as in the
present study. Thus, by combining the two studies, we have
been able to compare the impact of fasting (no meal and the
use of glucose-free dialysate) with the impact of a meal and
a glucose containing dialysate. The results are depicted in
Figure 4. In the fasting study bioactive IGF-I was reduced by
40%, whereas IGFBP-1 increased by 5-fold. Total IGF-I
levels remained stable at all time points during HD com-
pared with baseline, but declined 11% after the HD session
(from 180 ± 61 μg/L at baseline to 161 ± 63 μg/L at
300 min, p < 0.01; data not shown).
ATime (min)























































Figure 4 Relative changes in serum bioactive IGF-I and IGFBP-1. Relative changes in bioactive IGF-I (A) and IGFBP-1 (B) on no treatment
(black circles), glucose infusion (open circles), and glucose-insulin infusion (black triangles) study days in the present study compared with relative
changes in our previous study on fasting patients (empty triangles and dashed line). Data are expressed as mean ± SEM.
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http://www.biomedcentral.com/1471-2369/14/80Removal fraction of insulin and insulin aspart
As depicted in Table 2, a marked reduction in serum con-
centrations of both insulin and insulin aspart were ob-
served from the arterial site to the venous site of the
dialyser at the beginning (0 min), midway (120 min), and
at the end (240 min) of the HD session (p < 0.001 for each
comparison). The removal fraction did not differ between





0 min NT [insulin] 184 ± 91 57 ± 37 75 (58; 85)
G [insulin] 371 ± 274 119 ± 100 70 (63; 76)
GI [insulin] 253 ± 212 85 ± 91 72 (62; 79)
GI [insulin aspart] 481 ± 227 155 ± 56 67 (56; 75)
120 min NT [insulin] 87 ± 63 40 ± 30 55 (50; 59)
G [insulin] 294 ± 237 146 ± 133 53 (49; 56)
GI [insulin] 194 ± 163 94 ± 89 55 (49; 59)
GI [insulin aspart] 462 ± 181 225 ± 75 50 (45; 56)
240 min NT [insulin] 30 ± 20 17 ± 14 52 (32; 67)
G [insulin] 162 ± 115 90 ± 70 47 (44; 51)
GI [insulin] 74 ± 41 39 ± 22 48 (38; 56)
GI [insulin aspart] 464 ± 159 250 ± 114 48 (39; 55)
Abbreviations: NT, no treatment; G, glucose infusion; GI, glucose-insulin
infusion; A-site, arterial site; V-site, venous site of the dialyser; RF,
removal fraction.
*P < 0.001 for comparison of insulin and insulin aspart concentrations between
the A- and V-site at each time point and study day.
**The RF of insulin did not differ between study days and were similar for
insulin and insulin aspart. From 0 to 120 min the RF declined for both insulin
(p < 0.001, overall) and insulin aspart (p = 0.006), whereas the changes in the
RF from 120 to 240 min did not reach statistical significance. Data are
expressed as mean ± SD for insulin concentrations and mean (95% confidence
interval) for RF.The removal fraction, however, declined from the begin-
ning to midway of the HD session for both insulin (p <
0.001, overall) and for insulin aspart (p = 0.006), but then
stayed constant until the end of the HD session.
Inflammatory biomarkers
Changes in inflammatory biomarkers from HD start to
2 h post-HD (360 min) are depicted in Table 3. None of
the investigated biomarkers showed any differences in
the changes over time between study days. Compared
with the start of HD there was a significant overall in-
crease in both plasma albumin and fibrinogen concen-
trations at 360 min (p < 0.001 for both). From HD start
to the end of the study, no changes were observed in
overall concentrations of hsCRP, IL-6, or TNF-α,
whereas overall concentrations of plasma IL-1β declined
(p = 0.002).
Discussion
The present study investigated the effect of maintaining
hyperinsulinemia during HD by either glucose or
glucose-insulin infusion on serum bioactive IGF-I and
plasma IL-6. Although much higher serum insulin levels
were obtained when glucose or glucose-insulin infusion
was added to the meal, this had no further impact on
serum levels of bioactive IGF-I or IGFBP-1 during HD
than the meal alone. In contrast to the postprandial
intradialytic rise in bioactive IGF-I and concomitant fall
in IGFBP-1 observed in the present study, we previously
reported that HD in the fasting state results in a marked
reduction in bioactive IGF-I and a five-fold increase in
IGFBP-1 [23]. The observations in our previous study
were explained by the fasting state of the patients and
the use of a glucose-free dialysate resulting in very low
Table 3 Changes in inflammatory biomarkers during the experiments
Inflammatory
biomarkers
HD start End of study pa pb
(0 min) (360 min)
P-Albumin (g/L) Overall: 38.8 ± 2.1 Overall: 40.4 ± 2.5 0.12 < 0.001
Mean ± SD NT: 39.5 ± 1.4 NT: 41.3 ± 2.3
G: 38.1 ± 1.9 G: 40.4 ± 2.7
GI: 38.6 ± 2.8 GI: 39.6 ± 2.4
P-Fibrinogen (μmol/L) Overall: 11.7 ± 1.7 Overall: 12.8 ± 1.8 0.12 < 0.001
Mean ± SD NT: 11.9 ± 1.9 NT: 13.0 ± 2.0
G: 11.6 ± 1.6 G: 12.6 ± 1.6
GI: 11.7 ± 1.9 GI: 12.8 ± 2.0
S-hsCRP (mg/L) Overall: 4.52 [0.40-10.68] Overall: 4.67 [0.44-11.25] 0.61 0.55
Median [range] NT: 4.75 [0.58-10.08] NT: 6.06 [0.55-11.25]
G: 3.21 [0.50-8.20] G: 3.35 [0.57-7.96]
GI: 6.48 [0.40-10.68] GI: 6.40 [0.44-10.23]
P-IL-1β (ng/L) Overall: 0.042 [0.010-0.185] Overall: 0.039 [0.010-0.095] 0.68 0.002
Median [range] NT: 0.042 [0.011-0.185] NT: 0.031 [0.011-0.049]
G: 0.041 [0.010-0.157] G: 0.039 [0.010-0.095]
GI: 0.043 [0.010-0.166] GI: 0.039 [0.029-0.079]
P-IL-6 (ng/L) Overall: 0.19 [0.04-2.33] Overall: 0.18 [0.02-0.89] 0.96 0.25
Median [range] NT: 0.14 [0.08-1.84] NT: 0.19 [0.04-0.89]
G: 0.21 [0.04-0.97] G: 0.17 [0.05-0.34]
GI: 0.20 [0.06-2.33] GI: 0.30 [0.02-0.45]
P-TNF-α (ng/L) Overall: 0.42 [0.02-9.36] Overall: 0.29 [0.02-1.82] 0.76 0.09
Median [range] NT: 0.27 [0.10-8.53] NT: 0.27 [0.02-1.82]
G: 0.51 [0.02-2.89] G: 0.26 [0.03-1.75]
GI: 0.36 [0.25-9.36] GI: 0.46 [0.25-1.33]
Abbreviations: HD, hemodialysis; NT, no treatment; G, glucose infusion; GI, glucose-insulin infusion; hsCRP, High-sensitivity CRP; IL-1β, interleukin-1β; IL-6,
interleukin-6; TNF-α, tumor necrosis factor α.
ap-value for comparison of differences in the change over time between no treatment (NT), glucose infusion (G), and glucose-insulin infusion (GI) study days.
bp-value for comparison of overall change in biomarkers from HD start to the end of the study.
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http://www.biomedcentral.com/1471-2369/14/80insulin levels (< 10 pM) during the HD sessions. Taken
together, postprandial insulin secretion blocked hepatic
IGFBP-1 production and stimulated serum bioactive
IGF-I with no further effect of adding glucose or
glucose-insulin infusion to the meal. On the other hand,
although no differences in serum bioactive IGF-I were
observed between study days, our two studies have dem-
onstrated that in non-diabetic HD patients a meal can
prevent the HD-associated negative changes in the IGF
system observed under fasting conditions. Interestingly,
protein turnover studies have almost unanimously dem-
onstrated that intradialytic nutritional supplementation,
administered either parenterally or orally, prevent the
HD-associated muscle protein catabolism observed
under fasting conditions and result in an anabolic
muscle protein response [24,41,42].
In healthy individuals circulating IGFBP-1 levels are
inversely correlated with serum insulin levels, and serum
insulin levels between 65 and 172 pmol/L promptlyinhibits the hepatic IGFBP-1 production [29,43]. In ac-
cordance with this, the present study demonstrated a
significant negative association between serum IGFBP-1
and insulin levels. Moreover, on NT study days IGFBP-1
reached nadir values and began to rise when postpran-
dial serum insulin levels dropped below 100 pmol/L at
120 min (~4 h after the meal). In contrast, serum
IGFBP-1 concentrations were suppressed during the G
and GI study days until the post-HD period when glucose
infusions were tapered off, resulting in reduced insulin
levels. The rise in IGFBP-1 levels 3–4 h after the meal on
NT study days is similar to the postprandial response
reported in healthy individuals, hereby supporting that the
normal feedback of insulin on IGFBP-1 is preserved in
HD patients [29,44,45]. Most likely, the steep rise in
IGFBP-1 levels observed in the post-HD period on GI
study days was caused by the rapid and pronounced de-
cline in BG levels blocking the secretion of endogenous
insulin and thereby stimulating IGFBP-1 secretion [46].
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http://www.biomedcentral.com/1471-2369/14/80Insulin plays a central role in muscle metabolism both
directly by inhibiting muscle proteolysis [5,20] and indir-
ectly through the IGF-system. Insulin has a molecular
weight (MW) of 5.8 kDa and usually circulates in its free
form explaining that it is almost completely cleared from
the blood during HD [39,47]. In contrast, more than
99% of IGF-I (MW 7.5 kDa) circulates bound to IGFBPs
and therefore avoids clearance by the dialyser [23,39]. In
one report, insulin was undetectable in the filtrate des-
pite a high elimination rate and it was suggested that in-
sulin was cleared from the blood by adsorption onto the
dialyser membrane (a polysulfone membrane) [48]. In
our study, we used a high-flux polysulphone membrane,
which is reported to have a higher clearance rate of insu-
lin than other membrane types [47]. During HD, the RF
declined for both insulin and insulin aspart. Although
speculative, this observation can be explained by satur-
ation of the insulin binding sites on the polysulphone
membrane during the HD session. Even though serum
insulin levels were adequately raised by the meal, the
high RF of insulin may still play a role for HD-associated
muscle protein catabolism in diabetics without a residual
β-cell function. In most European countries meals are
routinely offered as an integrated part of the HD treat-
ment. In contrast, some dialysis clinics in the USA have
rules against meal intake during HD due to the risk of
postprandial hypotension, choking/aspiration, and infec-
tion [49].
In the present study, no anti-inflammatory effect of in-
sulin was detected as none of the investigated inflamma-
tory markers showed any difference in the change over
time between study days. In comparison, a recent cross-
over study showed that compared with a 4-h HD session
conducted during fasting but preceded by a breakfast
meal, the addition of low-dose insulin infusion (Actrapid
2 IU/h) during HD resulted in a reduction in plasma CRP,
whereas IL-6 and TNF-α levels were unaffected [32].
With respect to overall changes in acute-phase reac-
tants, we found a highly significant increase in overall
plasma albumin and fibrinogen from HD start to 2 hrs
post-HD, whereas serum levels of hsCRP did not
change. The rise in plasma albumin is counterintuitive
since HD is an inflammatory event and albumin is
considered a negative acute-phase reactant. The find-
ing is nevertheless consistent with published literature,
in which a coordinated increase in the hepatic frac-
tional synthesis rates of albumin and fibrinogen in re-
sponse to HD has been reported, and presumed to be
mediated by an intradialytic rise in IL-6 and by amino
acids derived from muscle catabolism [15,16,50,51].
Previous reports on changes in CRP levels during HD
are inconsistent as some studies show an increase
[32,51,52] and others no change [6,16,53]. The concen-
trations of IL-6 and TNF-α were unchanged in ourstudy, whereas IL-1β concentrations fell. This is in con-
trast to previous studies that almost unanimously have
reported a rise in IL-6 levels and either no change or an
increase in IL-1β and TNF-α in response to HD
[15,16,51,53]. The discrepancy in plasma IL-6 changes
during HD may in part be explained by differences in
patient characteristics as patients included in our study
were well-nourished and showed no sign of infection or
inflammation.
A limitation of this study is that we did not include a
study day, where patients were kept fasting during the
entire experiment. Therefore we compared the results of
the present study with the results of a study published in
2010, where patients were in the fasting state before and
during the HD session. The two studies were conducted
at the same hemodialysis department and were compar-
able with respect to patient groups and delivered HD
dose. Nevertheless, the comparisons have to be
interpreted with caution. First of all, although the two
patient groups were similar in the two studies the
between-group variation is much greater than in a cross-
over study and therefore the power to detect a difference
is smaller. Secondly, although samples were analyzed at
the same laboratory they were not analyzed simultan-
eously. Thirdly, hemodialysis procedures changed in the
time period between the two studies and therefore we
used different high-flux membranes (FX80, Fresenius
Medical Care, Bad Homburg, Germany versus Polyflux
H17, Gambro, Sweden) and dialysate compositions (glu-
cose containing versus non-glucose containing). Despite
this reservation, the differences in the changes in serum
levels of bioactive IGF-I and IGFBP-1 between the two
studies were of such a magnitude that we find it highly
unlikely that they were caused solely by the above men-
tioned study differences. Finally, the patients included in
the present study were non-diabetic and moderately to
well nourished. It is therefore possible that results are
not applicable to the general HD patient population,
which also includes patients with diabetes as well as
malnourishment.
Conclusions
Adding glucose or glucose-insulin infusion to a meal had
no further stimulating effects on serum IGF-I during a
HD session. The study, however, demonstrated that a
meal alone changed the negative response observed in the
IGF-I system during HD in the fasting state to a positive
response with a rise in bioactive IGF-I. These changes in
bioactive IGF-I during HD support the anabolic role of
intradialytic nutritional support. Hyperinsulinemia during
HD had no effect on biomarkers of inflammation.
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